In some people with an overactive thyroid treated with propylthiouracil, a rare immune-related condition called ANCA-positive vasculitis can occur, causing joint pain, skin discoloration, and swelling; stopping the drug usually leads to improvement.
Claim Context
Propylthiouracil use in patients with Graves' disease is associated with the development of ANCA-positive vasculitis, characterized by symptoms including arthritis, bone pain, livedo reticularis, and edema, which typically resolve after drug discontinuation.
“A 38-year-old woman with a history of Graves’ disease was on long-term treatment with propylthiouracil (PTU), presented with severe bone pain, arthritis and edema in both feet. The patient’s manifestations were resolved with discontinuation of PTU, iodine therapy, and corticosteroid administration.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether propylthiouracil use significantly increases the risk of ANCA-positive vasculitis compared to other anti-thyroid drugs or no drug, across multiple populations and study designs.
A systematic review and meta-analysis of all published cohort and case-control studies comparing incidence of ANCA-positive vasculitis in Graves' disease patients treated with propylthiouracil versus methimazole or no anti-thyroid drug, with standardized diagnostic criteria, adjustment for age, sex, and treatment duration, and pooled risk ratios with 95% confidence intervals.
Whether initiating propylthiouracil in euthyroid Graves' disease patients leads to higher rates of ANCA-positive vasculitis compared to methimazole over 12 months.
A double-blind, randomized controlled trial enrolling 500 adults aged 18–65 with newly diagnosed Graves' disease, randomized to receive either propylthiouracil (150 mg/day) or methimazole (10 mg/day) for 12 months, with monthly monitoring for ANCA titers, clinical vasculitis symptoms (joint pain, skin changes, renal function), and adjudicated diagnosis by rheumatologists.
The incidence rate of ANCA-positive vasculitis among Graves' disease patients treated with propylthiouracil compared to those treated with methimazole over a 5-year period.
A prospective cohort study following 10,000 adults with Graves' disease treated with propylthiouracil and 10,000 treated with methimazole across multiple endocrinology centers, with annual ANCA testing, symptom screening, and adjudicated vasculitis diagnosis by blinded rheumatologists over 5 years.
Whether prior propylthiouracil exposure is more common in patients diagnosed with ANCA-positive vasculitis than in matched controls without vasculitis.
A multicenter case-control study comparing 200 patients with biopsy-confirmed ANCA-positive vasculitis to 400 matched controls without vasculitis, assessing prior exposure to propylthiouracil, methimazole, or no anti-thyroid drug, with adjustment for age, sex, duration of hyperthyroidism, and comorbidities.
That ANCA-positive vasculitis can occur in association with propylthiouracil use, as a rare clinical observation.
A detailed clinical description of a patient with Graves' disease on propylthiouracil who develops ANCA positivity, vasculitis symptoms (arthritis, livedo reticularis, edema), and resolution after drug withdrawal, with laboratory and histopathological confirmation.